Plasma B-type natriuretic peptide concentration in β-thalassaemia patients

Background: Plasma B-type natriuretic peptide (BNP) concentration has significant diagnostic accuracy and prognostic value in various forms of heart disease. Whether BNP is also useful in the evaluation and management of thalassaemia heart disease remains to be determined. Methods and results: Eighty three thalassaemia major patients; 8 with acutely decompensated heart failure (New York Heart Association [NYHA] class III or IV, group A), 25 with NYHA class 11 symptoms and impaired systolic left ventricular function (ejection fraction <55% or fractional shortening <30%, group B) and 50 with normal systolic function (group C), as well as 50 healthy controls, were studied. Assessment included history, physical examination, Doppler echocardiography and plasma BNP determination. Mean BNP levels were 431 219 pg/mL (range, 283-890 pg/mL) in group A, 158 +/- 31 pg/mL in group B, 1763 +/- 54 pg/mL in group C and 43 +/- 24 pg/mL in controls. BNP levels were significantly higher in group A (p < 0.001), but did not differ between groups B and C. Moreover, BNP was not correlated with left ventricular end-diastolic diameter, left ventricular mass, right ventricular diameter index, Doppler diastolic indexes (except in group C), the mean 2-year serum ferritin concentration or the peak serum ferritin concentration in any of the three patient groups. Conclusion: A potential deficiency of BNP-related neurohormonal mechanisms may impair its clinical usefulness in thalassaemia major. (C) 2006 European Society of Cardiology. Published by Elsevier B.V All rights reserved.